S100A12 Gene Expression Is Increased in Peripheral Leukocytes in Chronic Kidney Disease Stage 4-5 Patients with Cardiovascular Disease
Nephron Clinical Practice · 06.08.2013 · 123 (3-4) · 202-208
DOI: 10.1159/000353808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephron Clinical Practice, online erschienen am 06.08.2013. Verfasst von Masaki Hara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Tokyo Metropolitan Komagome General Hospital, Tokyo, Japan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background/Aims: S100A12 induces vascular inflammation contributing to the development of atherosclerosis. Serum S100A12 concentration is shown to be elevated in patients with chronic kidney disease (CKD), however the reason remains unclear.
Methods
Transcriptional levels of S100A12 and RAGE (receptor for advanced glycation end products) were measured in peripheral leukocytes by quantitative real-time RT-PCR. Subjects were 40 patients with CKD stage 4-5, 20 of whom were affected with cardiovascular disease (CVD), and 20 healthy subjects. Serum concentrations of S100A12 and soluble RAGE were measured using enzyme-linked immunosorbent assay.
Results
The serum concentration of S100A12 was significantly higher in CKD patients than in healthy subjects (78.5 ± 70.5 vs. 23.7 ± 19.2 ng/ml, p = 0.0035), but that of soluble RAGE was not. The relative quantity of S100A12 mRNA was significantly greater in leukocytes from CKD patients than in those from healthy subjects [mean (95% confidence interval of the mean): 3.1 (2.2-3.9) vs. 1.2 (0.8-1.7), p = 0.0001], however that of RAGE mRNA was not. The serum concentration of S100A12 was significantly correlated with the relative quantity of S100A12 mRNA among uremic CKD patients (r2 = 0.656, p < 0.0001). Both the serum concentration and gene expression of S100A12 were significantly higher in patients who had CVD than in those who did not.
Conclusion
Excessive expression of the S100A12 gene in uremic leukocytes is relevant to its increased serum concentration, particularly in those affected with CVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, Tokyo Metropolitan Komagome General Hospital, Tokyo, Japan.
Zitieren
APA
Hara, M., Ando, M., Morito, T., Nokiba, H., Iwasa, Y., Tsuchiya, K., & Nitta, K. (2013). S100A12 Gene Expression Is Increased in Peripheral Leukocytes in Chronic Kidney Disease Stage 4-5 Patients with Cardiovascular Disease. Nephron Clinical Practice, 123(3-4), 202-208. https://doi.org/10.1159/000353808
Vancouver
Hara M, Ando M, Morito T, Nokiba H, Iwasa Y, Tsuchiya K, et al. S100A12 Gene Expression Is Increased in Peripheral Leukocytes in Chronic Kidney Disease Stage 4-5 Patients with Cardiovascular Disease. Nephron Clinical Practice. 2013;123(3-4):202-208. doi:10.1159/000353808
BibTeX
@article{Hara2013,
author = {Hara, Masaki and Ando, Minoru and Morito, Taku and Nokiba, Hirohiko and Iwasa, Yuko and Tsuchiya, Ken and Nitta, Kosaku},
title = {S100A12 Gene Expression Is Increased in Peripheral Leukocytes in Chronic Kidney Disease Stage 4-5 Patients with Cardiovascular Disease},
journal = {Nephron Clinical Practice},
year = {2013},
volume = {123},
number = {3-4},
pages = {202--208},
doi = {10.1159/000353808}
}
EUVIMED